Silverback Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.31
- Today's High:
- $7.54
- Open Price:
- $7.54
- 52W Low:
- $3.99
- 52W High:
- $9.65
- Prev. Close:
- $7.48
- Volume:
- 552468
Company Statistics
- Market Cap.:
- $679.49 million
- Book Value:
- 2.607
- Revenue TTM:
- $219000
- Operating Margin TTM:
- -27549.31%
- Gross Profit TTM:
- $1.32 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -24.74%
- Return on Equity TTM:
- -38.03%
Company Profile
Silverback Therapeutics Inc had its IPO on 2020-12-04 under the ticker symbol SPRY.
The company operates in the Healthcare sector and Biotechnology industry. Silverback Therapeutics Inc has a staff strength of 29 employees.
Stock update
Shares of Silverback Therapeutics Inc opened at $7.54 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.31 - $7.54, and closed at $7.35.
This is a -1.74% slip from the previous day's closing price.
A total volume of 552,468 shares were traded at the close of the day’s session.
In the last one week, shares of Silverback Therapeutics Inc have increased by +3.38%.
Silverback Therapeutics Inc's Key Ratios
Silverback Therapeutics Inc has a market cap of $679.49 million, indicating a price to book ratio of 0 and a price to sales ratio of 329.6943.
In the last 12-months Silverback Therapeutics Inc’s revenue was $219000 with a gross profit of $1.32 million and an EBITDA of $-59987000. The EBITDA ratio measures Silverback Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Silverback Therapeutics Inc’s operating margin was -27549.31% while its return on assets stood at -24.74% with a return of equity of -38.03%.
In Q2, Silverback Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 97.8%.
Silverback Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Silverback Therapeutics Inc’s profitability.
Silverback Therapeutics Inc stock is trading at a EV to sales ratio of 264.7597 and a EV to EBITDA ratio of -26.5708. Its price to sales ratio in the trailing 12-months stood at 329.6943.
Silverback Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $258.75 million
- Total Liabilities
- $10.05 million
- Operating Cash Flow
- $44.97 million
- Capital Expenditure
- $30000
- Dividend Payout Ratio
- 0%
Silverback Therapeutics Inc ended 2024 with $258.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $258.75 million while shareholder equity stood at $248.55 million.
Silverback Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.05 million in other current liabilities, 9000.00 in common stock, $-109269000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.02 million and cash and short-term investments were $252.21 million. The company’s total short-term debt was $233,000 while long-term debt stood at $0.
Silverback Therapeutics Inc’s total current assets stands at $255.03 million while long-term investments were $0 and short-term investments were $133.19 million. Its net receivables were $962000.00 compared to accounts payable of $9.65 million and inventory worth $-962000.00.
In 2024, Silverback Therapeutics Inc's operating cash flow was $44.97 million while its capital expenditure stood at $30000.
Comparatively, Silverback Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.35
- 52-Week High
- $9.65
- 52-Week Low
- $3.99
- Analyst Target Price
- $14
Silverback Therapeutics Inc stock is currently trading at $7.35 per share. It touched a 52-week high of $9.65 and a 52-week low of $9.65. Analysts tracking the stock have a 12-month average target price of $14.
Its 50-day moving average was $6.97 and 200-day moving average was $7.16 The short ratio stood at 16.93 indicating a short percent outstanding of 0%.
Around 3470.6% of the company’s stock are held by insiders while 5898.2% are held by institutions.
Frequently Asked Questions About Silverback Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.